Logotype for ProMIS Neurosciences Inc

ProMIS Neurosciences (PMN) investor relations material

ProMIS Neurosciences Evercore ISI 8th Annual HealthCONx Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for ProMIS Neurosciences Inc
Evercore ISI 8th Annual HealthCONx Conference summary2 Dec, 2025

State of the business and industry

  • Focused on advancing a phase I-B clinical study for Alzheimer's, with consistent progress and guidance maintained throughout the year.

  • The Alzheimer's treatment landscape remains open for novel drugs due to limitations and side effects of current market options.

  • Enrollment for the phase I-B trial is on track to complete by year-end, with interim analysis expected in Q2 and top-line results in Q4 of the following year.

  • The lead asset, PMN310, is an amyloid beta monoclonal antibody targeting toxic oligomers rather than plaque.

Scientific rationale and differentiation

  • Industry focus has shifted from targeting amyloid plaque to toxic oligomers, which are now seen as the main drivers of disease progression.

  • PMN310 is designed to selectively target low molecular weight oligomers, believed to be the most toxic species.

  • Competing drugs often cross-react with plaque, leading to side effects like ARIA, while PMN310 aims to minimize this risk.

Clinical trial design and safety

  • The phase I-B PRECISE-AD trial targets 128 patients to ensure at least 100 completers, with three dosing cohorts (5, 10, 20 mg/kg).

  • Safety profile has been strong, with ARIA rates expected to be similar to placebo and lower than other drugs.

  • Interim analysis will focus on safety and biomarker endpoints, not direct clinical efficacy.

  • Biomarkers such as pTau217, pTau243, neurogranin, GFAP, and SNAP-25 will be used to infer potential clinical benefit.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next ProMIS Neurosciences earnings date

Logotype for ProMIS Neurosciences Inc
Q4 202530 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next ProMIS Neurosciences earnings date

Logotype for ProMIS Neurosciences Inc
Q4 202530 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

ProMIS Neurosciences Inc is a Canada-based biotechnology company focused on the discovery and development of antibody therapeutics for neurodegenerative diseases. The company uses a proprietary computational platform to design monoclonal antibodies that selectively target toxic misfolded proteins implicated in conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. ProMIS conducts preclinical and early-stage clinical development in collaboration with academic and industry partners. The company is headquartered in Toronto, Ontario, and its shares are listed on the TSX.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage